CEO Pia Renaudin buys shares for SEK 5.5 million in Senzime
Press release: Uppsala, July 17th, 2020. Senzime AB (publ) today announces that CEO Pia Renaudin has acquired 300,000 shares in the company at a price of SEK 18.50 per share, corresponding to a value of approximately SEK 5.5 million. The shares have been acquired from a consortium of principal owners consisting of Segulah Venture AB, Adam Dahlberg and Philip Siberg (through company).
” Through this transaction, we achieve a strong CEO incentive that will create value for all Senzime’s shareholders”, says Philip Siberg, Chairman of the Board and representative of the sellers.
After the acquisition, Pia Renaudin owns 306,000 shares and 400,000 warrantsin Senzime AB.
About Senzime Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients ' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, email@example.com, is Certified Adviser for Senzime. www.senzime.com
Explore our patient monitoring solutions
Get product details
How can Senzime’s products help to eliminate in-hospital complications?
Contact us to discuss your needs or schedule a product demo.